Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Legend Biotech ( (LEGN) ) has issued an announcement.
On June 5, 2025, Legend Biotech Corporation announced the appointment of Peter Salovey, Ph.D., as Lead Independent Director, effective immediately. Dr. Salovey, who has been an independent director since August 2024, is expected to leverage his extensive leadership experience to enhance communication among the Board of Directors, management, and shareholders, potentially guiding the company through strategic growth phases.
The most recent analyst rating on (LEGN) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s overall score reflects strong revenue growth and strategic plans for profitability, but is tempered by current financial losses and negative technical indicators. The positive outlook from the earnings call adds optimism, but cash flow issues and valuation concerns weigh down the score.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of novel therapies. The company is known for its innovative approaches in the field of cell therapy, aiming to address unmet medical needs in the global market.
Average Trading Volume: 1,552,080
Technical Sentiment Signal: Sell
Current Market Cap: $5.23B
For an in-depth examination of LEGN stock, go to TipRanks’ Stock Analysis page.